This Edition
ARTICLE | Deals
With Ideaya deal, GSK bulks up synthetic lethality side of oncology business
GSK and Ideaya’s deal is the second in a month to move a pharma deeper into synthetic lethality
Karen Tkach Tuzman, Associate Editor
June 17, 2020 2:50 AM UTC
Access this Article
Request a Trial
Purchase This Article
Log in
BCIQ Company Profiles
Ideaya Biosciences Inc.
GlaxoSmithKline plc
BCIQ Company Profiles
Ideaya Biosciences Inc.
GlaxoSmithKline plc